From the Cancer Research Campaign & University of
Manchester, Department of Medical Oncology, Christie Hospital National
Health Service Trust, Manchester M20 4BX, United Kingdom, the
School of Biological Sciences, University of Liverpool,
Liverpool L69 7ZB, United Kingdom, and the ** Division of Biochemistry,
Biomedical Research Center, Osaka University Medical School,
Osaka 565, Japan
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have demonstrated by affinity chromatography that hepatocyte growth factor/scatter factor (HGF/SF) binds strongly to dermatan sulfate (DS), with a similar ionic strength dependence to that previously seen with heparan sulfate (HS). Analysis of binding kinetics on a biosensor yields an equilibrium dissociation constant, KD, of 19.7 nM. This corresponds to a 10-100-fold weaker interaction than that with HS, primarily due to a faster dissociation rate of the complex. The smallest DS oligosaccharide with significant affinity for HGF/SF by affinity chromatography appears to be an octasaccharide. A sequence comprising unsulfated iduronate residues in combination with 4-O-sulfated N-acetylgalactosamine is sufficient for high affinity binding. The presence of 2-O-sulfation on the iduronate residues does not appear to be inhibitory. These observations concur with our previous suggestions, from analyses of HS binding (Lyon, M., Deakin, J. A., Mizuno, K., Nakamura, T., and Gallagher, J.T. (1994) J. Biol. Chem. 269, 11216-11223), that N-sulfation of hexosamines and 2-O-sulfation of iduronates are not absolute requirements for glycosaminoglycan binding to HGF/SF. This is the first described example of a high affinity interaction between a growth factor and DS, and is likely to have significant implications for the biological activity of this paracrine-acting factor.
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Hepatocyte growth factor/scatter factor (HGF/SF)1 is a pleiotropic factor with the ability to influence the growth, motility, differentiation, and morphogenesis of its target cells (for a recent review, see Ref. 1). It acts in a paracrine manner, with the major secretors being fibroblasts, vascular smooth muscle cells, nonparenchymal liver cells, etc., whereas those cells that possess the requisite tyrosine kinase receptor (Met) are primarily epithelial and endothelial cells. Recent evidence suggests that multipotent and erythroid hemopoietic progenitor cells are also responsive to HGF/SF. The HGF/SF-Met system appears to operate primarily during the morphogenetic and differentiation events occurring in organogenesis, as well as in the repair of organ damage in the adult (reviewed in Ref. 1). Aberrant expression of HGF/SF and/or Met has been strongly implicated in tumor progression, particularly in the acquisition of an invasive malignant phenotype (2-5). This presumably results from its ability to directly stimulate the growth and motility of tumor cells, as well as increasing the secretion of matrix-degrading proteases (6), thereby facilitating invasion of the surrounding stroma. Additionally, its potent angiogenic action (7, 8) may contribute to the development of a tumor vasculature, which is essential for sustaining an expanding tumor mass.
In addition to Met, HGF/SF also interacts in vitro with the heparan sulfate (HS) chains of heparan sulfate proteoglycans (HSPGs) (9). The latter probably constitute the more abundant, but relatively lower affinity, HGF/SF-binding sites present on most cells (10). The interaction of HGF/SF with cell surface HSPGs may facilitate its binding to Met and the subsequent activation of its tyrosine kinase activity (11-15). The HGF/SF-binding site is present within the iduronate- and sulfate-rich domains of HS, and its structure has been partially elucidated (9, 16). Additionally, the affinity of the HGF/SF-HS interaction is known to be high with a KD of 0.2-3 nM.2
Dermatan sulfate (DS), although biosynthetically unrelated and
compositionally distinct from HS, nevertheless does possess some
similar organizational features (for a review, see Ref. 17). DS
contains N-acetylgalactosamine rather than
N-acetylglucosamine, and the glycosidic linkages are
alternating /
1
3 and
1
4, rather than all
/
1
4.
However, both glycosaminoglycans (GAGs) possess iduronate-rich domains
of variable length, formed by epimerization of glucuronates to
iduronates, although in DS the adjacent hexosamines are
N-acetylated rather than being specifically
N-sulfated (a prerequisite for epimerization in HS).
Whereas, in DS, the iduronate-linked hexosamines are relatively
uniformly O-sulfated on C-4, in HS, they can become
6-O-sulfated, but to a lesser extent. In both GAGs,
additional sulfation can also occur at C-2 on the iduronates, although
generally less frequently in DS. Overall, DS experiences much less
additional sulfation within the iduronate-rich domains, compared with
the glucuronate-rich sequences, than does HS, in which the great
majority of the overall chain sulfation is concentrated in such
domains.
The parallel occurrence of contiguous sequences of iduronate and adjacent sulfated hexosamines in both types of GAG may help to explain why DS, unlike the iduronate-lacking chondroitin sulfates (CS), often interacts relatively weakly with many HS/heparin-binding proteins, e.g. basic fibroblast growth factor (FGF) (18), platelet factor 4 (19), fibronectin (20), interleukin-7 (21), and protein C inhibitor (22). Only in the specific case of heparin cofactor II has a comparable high affinity interaction with DS been demonstrated, and this is dependent upon the presence of a specific, highly sulfated DS oligosaccharide sequence (23, 24).
In the present study, we demonstrate that HGF/SF also binds to DS with high affinity. This gives further insight into the specific structural requirements for oligosaccharide binding to HGF/SF. The existence of this interaction is likely to have significant implications for the biological activity of this paracrine-acting, mesenchymal factor.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Materials-- Recombinant human HGF/SF was purified as described by Nakamura et al. (25). Porcine mucosal heparin, bovine mucosal dermatan sulfate, bovine kidney heparan sulfate, and shark cartilage chondroitin sulfate were purchased from Sigma (Poole, United Kingdom (UK)). Low molecular weight heparin (Innohep) was obtained from Leo Laboratories Ltd. (Princes Risborough, UK). Decorin proteoglycan, purified from bovine skin (26), was a generous gift from Dr. C. H. Pearson (University of Alberta, Edmonton, Alberta, Canada). Affi-Gel 10 and Bio-Gels P-2 and P-10 were obtained from Bio-Rad (Hemel Hempstead, UK). PD-10 desalting columns were from Pharmacia Biotech (Uppsala, Sweden). D-[6-3H]Glucosamine hydrochloride (20-45 Ci/mol) was from NEN Life Science Products (Stevenage, UK). Chondroitin ACI lyase (Flavobacterium heparinum; EC 4.2.2.5), chondroitin ACII lyase (Arthrobacter aurescens; EC 4.2.2.5), chondroitin ABC lyase (Proteus vulgaris; EC 4.2.2.4), and chondroitin B lyase (F. heparinum; no EC number assigned) were from Seikagaku Kogyo Co. (Tokyo, Japan). Mouse Balb/c 3T3 cells were from the American Type Culture Collection (ATCC). The FS8 fibroblast cell line was derived from fetal human skin (27). Madin-Darby canine kidney (MDCK) cells were kindly provided by Dr. E. Gherardi (Cambridge University Medical School, Cambridge, UK).
Preparation and Operation of HGF/SF Affinity Columns--
HGF/SF
affinity columns were prepared by coupling recombinant human HGF/SF to
Affi-Gel 10, in the presence of an excess of heparin to protect the
GAG-binding site, as described by Lyon et al. (9).
Radiolabeled poly- or oligosaccharides were applied to the HGF/SF
column in an ionic strength of 0.15 M at room
temperature, and then recirculated at least 10 times to maximize
binding. After washing with PBS, the column was eluted with an
increasing stepwise gradient of NaCl in 20 mM sodium
phosphate, pH 7.0. Fractions were collected and monitored for
radioactivity.
Purification of Radiolabeled Chondroitin/Dermatan Sulfate Chains-- Confluent cultures of either FS8 fibroblasts or Balb/c 3T3 cells, grown in minimum Eagle's medium containing 10% (v/v) heat-inactivated donor calf serum (Life Technologies Inc., Paisley, UK), were metabolically radiolabeled with 5 µCi/ml D-[6-3H]glucosamine hydrochloride for 24 h at 37 °C in a humidified atmosphere of 5% (v/v) CO2 in air. The culture medium was removed, and the cell layers were extracted with 1% (v/v) Triton X-100 in PBS at 4 °C for 1 h. The cellular extract was recombined with the culture medium, and Pronase was added to a final concentration of 0.1 mg/ml. After digestion at 37 °C for 2 h, the sample was heat-inactivated, filtered, and then applied to a DEAE-Sephacel column equilibrated with PBS containing 1% (v/v) Triton X-100. The column was washed with 0.2 M NaCl, 1% (v/v) Triton X-100, 20 mM sodium phosphate, pH 7.4, and then eluted with a linear gradient of 0.2-1.5 M NaCl in 1% (v/v) Triton X-100, 20 mM sodium phosphate, pH 7.4. The late-eluting peak, corresponding primarily to CS/DS chains, was recovered, dialyzed against distilled water, and concentrated to approximately 1 ml. The sample was treated with pH 1.5 nitrous acid (28) to degrade any contaminating HS, neutralized, and purified by chromatography on a Sepharose CL6B column (1.5 × 95 cm) eluted with 0.2 M NH4HCO3 at a flow rate of 12 ml/h. The high molecular weight CS/DS chains were collected and freeze-dried.
The heterogeneity of the major oligosaccharide fractions was further analyzed by electrophoresis on a 25-35% (w/v) gradient polyacrylamide gel, with a 5% (w/v) polyacrylamide stacking gel, followed by semidry electrotransfer to a positively charged nylon membrane and then fluorographic detection.Partial Depolymerization of Chondroitin/Dermatan Sulfate Chains and Purification of Iduronate-rich Oligosaccharide Species-- Purified 3H-labeled CS/DS chains were dissolved in 1 ml of 50 mM sodium acetate, pH 6.5, and digested with a mixture of 0.1 units/ml each of chondroitin ACI and ACII lyases at 37 °C for 24 h. A further addition of enzymes was made and the incubation continued for 4 h. The digest was then chromatographed on a Bio-Gel P-10 (fine grade) column (1 × 133 cm) eluted with 0.2 M NH4HCO3 at a flow rate of 5 ml/h. Fractions of 1 ml were collected, and aliquots were counted for radioactivity. Peaks corresponding to individual size fractions of enzyme-resistant oligosaccharides were individually collected, exhaustively freeze-dried, and then redissolved in distilled water. Samples of each size fraction, from hexa- to dodecasaccharides, were then applied to a ProPac PA1 (Dionex; 0.4 × 25 cm) strong anion-exchange HPLC column equilibrated with distilled water adjusted to pH 3.5 with HCl. After a wash with pH 3.5 water, the column was eluted with a linear gradient of 0-1 M NaCl, pH 3.5, at a flow rate of 1 ml/min. Fractions of 0.5 ml were collected and aliquots counted for radioactivity. Fractions corresponding to individual oligosaccharide peaks were concentrated by centrifugal vacuum evaporation, desalted on PD-10 columns eluted with distilled water, and then freeze-dried.
Disaccharide Compositional Analysis-- Oligosaccharide species were completely digested to disaccharides using a mixture of 40 mIU/ml each of chondroitin ABC and chondroitin B lyases in 50 mM NaCl, 50 mM Tris-HCl, pH 8.0, at 37 °C for 24 h. The digests were then resolved by chromatography on a Bio-Gel P-2 (superfine) column (1 × 47 cm) eluted with 0.1 M NH4HCO3 at a flow rate of 4 ml/h. Fractions corresponding to the disaccharide peaks were collected, freeze-dried, and then redissolved in 1 ml of distilled water adjusted to pH 3.5 with HCl. Samples were applied either to a ProPac PA1 (0.4 × 25 cm; Dionex) or a 5 µm Spherisorb (0.46 × 25 cm; Technicol, Stockport, UK) strong anion-exchange HPLC column equilibrated in pH 3.5 water. After a wash with pH 3.5 water, the column was eluted with a linear gradient of 0-1 M NaCl, pH 3.5, at a flow rate of 1 ml/min. Fractions of 0.5 ml were collected and counted for radioactivity. Disaccharide peaks were identified by comparison with the elution positions of known CS/DS disaccharide standards (Seikagaku Kogyo Co., Tokyo, Japan).
Binding of HGF/SF to MDCK Cells and Competition with Various
GAGs--
MDCK cells were seeded into the wells of a 96-well plate at
a density of 104 cells/well in minimum Eagle's medium
containing 5% (v/v) fetal calf serum. After 20 h, the culture
medium was removed and the confluent cell layer was washed with medium
containing 1% (v/v) fetal calf serum, 1% (w/v) bovine serum albumin,
10 mM HEPES, pH 7.4, at 4 °C. The cells were then
incubated with 0.2 ml/well of the above solution containing 5 ng/ml
125I-HGF/SF (prepared as described by Lyon et
al. in Ref. 9) in the presence of a range of concentrations
(0-100 µg/ml) of heparin, HS, DS, or CS. After incubation at 4 °C
for 4 h, the cells were washed five times with cold binding
solution (no HGF/SF or GAG). Cells were then solubilized in 1 M NaOH, and the released 125I radioactivity was
measured in a counter.
Kinetic Analysis of HGF/SF Binding to Dermatan Sulfate-- Bovine skin decorin (250 µg of decorin in 100 µl of distilled water) was biotinylated on its core protein by addition of three 10-µl aliquots of a 50 mM solution of succinimidyl-6-(biotinamido)hexanoate (Pierce & Warriner, Chester, UK) in dimethyl sulfoxide over a 24-h period. Biotinylated decorin was separated from unreacted biotin reagent, by passage over a PD-10 desalting column eluted with distilled water, and then lyophilized.
Binding reactions were performed in an IAsys resonant mirror biosensor (Affinity Sensors, Cambridge, UK) using three-dimensional carboxymethyldextran surfaces. The surfaces were derivatized with streptavidin, according to the manufacturer's instructions, and then loaded with the biotinylated decorin proteoglycan. All HGF/SF binding reactions were performed in PBS, pH 7.2, containing 0.02% (v/v) Tween 20 at 20 °C, and data were collected three times a second. HGF/SF, at a known concentration, was introduced into the cuvette in 100 µl of binding solution and its association to the immobilized decorin was monitored until a plateau was reached. The cuvette was then rapidly washed twice with PBS, 0.02% (v/v) Tween 20, pH 7.2, and the dissociation of HGF/SF from the immobilized decorin was followed. The decorin surface was regenerated by washing twice with 200 µl of 2 M NaCl, 10 mM sodium phosphate, pH 7.2, followed by re-equilibration with PBS, 0.02% (v/v) Tween 20, pH 7.2. Three independent sets of binding reactions at five different HGF/SF concentrations were carried out. The association and dissociation rate constants, ka and kd, respectively, were calculated from each set of association and dissociation curves, using the nonlinear curve-fitting FastFit software (Affinity Sensors) supplied with the instrument. The individual values of ka and kd, together with their associated errors, were then combined. HGF/SF did not itself bind to streptavidin-derivatized carboxymethyldextran surfaces.2 ![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Interaction of HGF/SF with CS/DS Chains and Oligosaccharides-- 3H-Labeled CS/DS chains purified from cultures of FS8 fetal human skin fibroblasts bound to an HGF/SF affinity column, but not a control column, at physiological pH and ionic strength. The bound CS/DS fraction was eluted over the range of 0.4-1.0 M NaCl with the majority being released by 0.8 M NaCl (Fig. 1). This is very similar behavior to that reported previously for the HS chains derived from the same cell line (9). CS/DS chains prepared from cultures of Balb/c 3T3 cells also bound and eluted with similar characteristics (data not shown).
|
|
|
Correlation between DS Oligosaccharide Structure and Affinity for HGF/SF-- The individual hexa-, octa-, deca-, and dodecasaccharide fractions in Fig. 2 were further resolved by preparative strong anion-exchange HPLC into molecular species with differing sulfation patterns. Comparisons of both their disaccharide compositions and their respective HGF/SF affinities, as determined by the concentration of NaCl required to elute them from a HGF/SF column, may help to elucidate the minimum specific structural requirements for this interaction. All four oligosaccharide size populations yielded surprisingly similar profiles upon strong anion-exchange HPLC. A single major species (labeled peak B in all cases), comprising 70-83% of the total population, was always present, together with a substantially less abundant (13-19%), later-eluting species (labeled peak C) (Fig. 4 and Table I). A minor, earlier-eluting species (labeled peak A) was also present in all four size populations, and the content of this species appeared to generally increase with oligosaccharide size (Table I). A fourth, highly charged, minor species (labeled peak D) was found only in the dodecasaccharide population (Fig. 4).
|
|
GAG Competition for the Binding of 125I-HGF/SF to MDCK Cells-- MDCK cells express cell surface HSPGs (30), to which HGF/SF binds, in addition to the tyrosine kinase receptor, Met. Increasing concentrations of exogenously added heparin effectively inhibits HGF/SF binding to a confluent MDCK monolayer, with an IC50 of approximately 70 ng/ml (Fig. 5). Bovine kidney HS, although also inhibitory, has a significantly higher IC50 of approximately 10 µg/ml. By comparison, a bovine mucosal DS preparation (disaccharide composition: 0.5% nonsulfated, 95.4% mono-4-O-sulfated, 2.3% mono-6-O-sulfated, 0.7% di-2,4-O-sulfated, and 1.1% di-2,6-O-sulfated disaccharides) is also inhibitory, but behaves quantitatively most similarly to the HS, with an IC50 of approximately 4 µg/ml (Fig. 5). CS is essentially inactive as an inhibitor of HGF/SF binding up to the maximum concentration tested of 0.1 mg/ml.
|
Kinetics of HGF/SF Binding to DS-- Decorin DSPG contains only a single DS chain (disaccharide composition: 3.2% nonsulfated, 85.7% mono-4-O-sulfated, 3.1% mono-6-O-sulfated, 7.5% di-2,4-O-sulfated, and 0.5% di-2,6-O-sulfated disaccharides) attached very close to the amino terminus of the core protein, and therefore ideal for a biosensor binding analysis. The core protein can be readily biotinylated for immobilization on a streptavidin-derivatized carboxymethyldextran surface. This leaves the GAG exposed, relatively free of the immobilized streptavidin and other GAG chains.
The association phase of the binding reaction between HGF/SF and DS was fast (Fig. 6, top panel) and the mean association rate constant was 1.58 (± 0.29) × 106 M
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have demonstrated by affinity chromatography that HGF/SF interacts with DS. Kinetic analysis on immobilized decorin DSPG in a biosensor reveals a strong interaction with a KD of 19.7 nM. Although lower than its affinity for HS, this remains a physiologically relevant, high affinity interaction with likely consequences for the biology of HGF/SF. Comparisons between the present data with DS and that previously obtained with HS (9) reveal further insights into the oligosaccharide-binding specificities of HGF/SF.
The smallest DS oligosaccharide with a noticeable affinity for HGF/SF corresponds to an octasaccharide, although higher apparent affinity is observed with dodecasaccharides, or larger. These elute from the HGF/SF affinity column with 0.6 M NaCl, whereas 0.8 M NaCl is required to elute the intact DS chain. This size-dependent behavior is reminiscent of the previously described interaction with HS, although with the latter hexasaccharides were the smallest oligosaccharides with significant affinity. This may reflect true differences in HGF/SF affinity for oligosaccharides excised from the two GAGs. However, for both HS and DS, specific enzymic scission techniques were used which produce even-numbered oligosaccharides. These may only closely approximate the minimal binding sequences, as they could still contain irrelevant terminal monosaccharides. The apparently higher affinity (by chromatography) seen with intact DS and HS, compared with excised oligosaccharides, may be a consequence of the inherent polyvalency of long chains for HGF/SF.
Previous studies demonstrated that HGF/SF binds specifically within the iduronate-rich, N-/O-sulfated domains of HS (9, 16). Interaction did not, however, appear to directly require the characteristic N-sulfates of these domains, as their specific removal failed to abrogate binding (9). It was also suggested that high affinity binding was more closely correlated with the presence of 6-O-sulfates than of 2-O-sulfates, and that the latter may make, at most, only a small contribution (9). In contrast, Ashikari et al. (16) suggested a definite requirement for clusters of iduronate-2-O-sulfates in combination with adjacent 6-O-sulfated hexosamines. The present study of the interaction with DS both complements and extends our understanding of HGF/SF's binding specificity. It immediately confirms that N-sulfates are nonessential, while iduronate residues are an absolute requirement (as CS does not bind to HGF/SF; Fig. 5). Importantly, there is no apparent requirement for 2-O-sulfation of these iduronates. HGF/SF-binding octa-, deca-, and dodecasaccharide fractions included molecular species that did not possess 2-O-sulfates (i.e.. HPLC peaks A and B), as well as those which did (i.e.. HPLC peaks C and D) (Fig. 4 and Table I). Indeed, the great majority of the dodecasaccharide fraction is able to bind to HGF/SF (Fig. 3) when 77% of its constituent species lack 2-O-sulfates (Fig. 4 and Table I). Likewise, the presence of 2-O-sulfates is clearly not inhibitory and might make a small additional contribution to binding affinity. The minimum structural requirement for the binding of DS to HGF/SF may thus be satisfied by the repeating sequence [IdoA-GalNAc(4-OSO3)]3 as found in a minimal octasaccharide (although whether all the IdoA residues are strictly necessary and whether a limited GlcA presence at certain positions could be permissible is at present not known). In the hexa- to dodecasaccharides excised by chondroitin ACI/ACII lyases, the above repeating disaccharide is by far the major component of the iduronate-rich domains in the Balb/c 3T3 DS. Indeed only 2.9% of the hexuronates are 2-O-sulfated compared with an estimated iduronate content of 33%. Likewise, the corresponding 2-O-sulfate contents of the bovine mucosal DS and bovine skin decorin DS are also low, being 1.8% and 8.0%, respectively.
Interestingly, the hexosamine sulfates, which presumably contribute to
the interaction with HGF/SF, are on C-4 of GalNAc in DS, but on C-6 of
GlcNS in HS. This would imply that the interactive charged groups
(i.e.. iduronate carboxyls and hexosamine sulfates) may have
a similar spatial disposition within the solution conformation of a
[-4IdoA1-4GlcNS(6-OSO3)
1-]n sequence in HS
as they do in a
[-4IdoA
1-3GalNAc(4-OSO3)
1-]n sequence in
DS, in order for similar contacts to be made within the binding site on
HGF/SF. This possibility is favored as a result of the conformational
plasticity of the iduronate ring. Various groups (31-33) have proposed
that the nonsulfated iduronate pyranose ring, within both DS and
HS/heparin, possesses a substantial conformational mobility with two
accessible conformations, the 1C4 chair and the
2S0 skew-boat, although additional feasible
conformers have been proposed (34). It is thus possible that the
inherent plasticity of this monosaccharide would allow for the
interaction with HGF/SF to itself determine the final adopted
conformation of the bound oligosaccharide sequence, as demonstrated in
the binding of a heparin hexasaccharide to basic FGF (35). The ability
of relatively small, high affinity binding oligosaccharides from DS and
heparin to successfully compete with each other for binding to HGF/SF also suggests that both GAGs probably bind to the same site in HGF/SF,
and not to two separate sites with distinct GAG specificities.
The sufficiency of nonsulfated iduronate coupled to monosulfated hexosamine for HGF/SF binding contrasts with the structural requirements for other DS-protein interactions. The binding of low density lipoproteins does not appear to strongly require iduronate, and affinity increases with the general level of sulfation (36, 37). Heparin cofactor II, on the other hand, displays considerable specificity (23, 24) in requiring a contiguous sequence of at least three disulfated disaccharides containing 2-O-sulfated iduronate, i.e. IdoA(2-OSO3)-GalNAc(4-OSO3).
The measured affinity of HGF/SF for the DS chains of bovine skin decorin (KD of 19.7 nM) is high and thus very likely to be physiologically significant. The KD is 10-100-fold higher than the corresponding interaction between HGF/SF and a range of mammary cell-derived HS species (0.2-3 nM). This higher KD results from a combination of a broadly similar association rate constant and an approximately 10-fold higher dissociation rate constant than observed with HS.2 The similarity in association rate constants may help to explain why DS and HS have similar potencies as inhibitors of HGF/SF binding to MDCK cells (Fig. 5).
Interestingly, the KD for the HGF/SF-DS interaction
is very similar to that measured for the acknowledged high affinity interaction of basic FGF with various mammary cell HS species (20-35
nM),3 and also
for that of interleukin-7 with heparin (25 nM) (21). It is
considerably higher than the affinity of acidic FGF for the same HS
species (KD of 0.4-8.6
µM).3 It also represents a very high affinity
by comparison with other studied interactions of DS with proteins,
e.g. heparin cofactor II (KD of
approximately 1 µM) (38) and low density lipoproteins
(KD 9 µM) (37). Indeed, this is the first recorded example of a high affinity interaction between a growth
factor and DS.
The high affinity of HGF/SF for DS may have significant physiological consequences for its distribution, stability, and activity. HGF/SF is synthesized by mesenchymal cells and secreted into a stromal environment relatively rich in DSPGs, such as decorin and biglycan. This has to be traversed in order for HGF/SF to act as a paracrine factor at the basolateral surface of epithelial and endothelial cells, where the Met receptor is preferentially expressed. An increasing gradient of affinity from the DSPG-rich environment of the stromal cells to the HSPG-rich basement membrane supporting the epithelial/endothelial cells may help to guide the delivery of HGF/SF to the epithelium/endothelium. The ability of DSPGs to rapidly capture HGF/SF in the extracellular matrix may also prevent uncontrolled diffusion as well as protecting it from proteolytic inactivation. A high capacity for binding of HGF/SF in the matrix may also create a potential reservoir of latent factor. This could be rapidly mobilized under the influence of matrix-degrading proteases during tissue remodeling and wound healing, as well as during tumor invasion. The potential release of HGF/SF at the edge of an expanding carcinoma could stimulate further tumor growth by promoting increased tumor cell proliferation, motility, and invasion, as well as providing a pro-angiogenic stimulus that could contribute to tumor vascularization. Functionally, it will be of particular interest to ascertain whether DS is also capable of facilitating the binding of HGF/SF to its receptor, in a similar way to that described for HS.
![]() |
ACKNOWLEDGEMENT |
---|
We thank Suzanne Bridge for secretarial assistance.
![]() |
FOOTNOTES |
---|
* This work was supported by grants from the Cancer Research Campaign (to M. L., J. A. D., and J. T. G.), the North West Cancer Research Fund (to H. R. and D. G. F.), and the Mizutani Foundation for Glycoscience.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Dept. of Medical Oncology, Christie CRC Research Centre, Christie Hospital NHS Trust, Wilmslow Rd., Manchester M20 4BX, United Kingdom. Tel.: 44-161-446-3202; Fax: 44-161-446-3269; E-mail: MLyon{at}picr.man.ac.uk.
1
The abbreviations used are: HGF/SF, hepatocyte
growth factor/scatter factor; GAG, glycosaminoglycan; HS, heparan
sulfate; HSPG, heparan sulfate proteoglycan; DS, dermatan sulfate;
DSPG, dermatan sulfate proteoglycan; CS, chondroitin sulfate; FGF,
fibroblast growth factor; HPLC, high performance liquid chromatography;
PBS, phosphate-buffered saline; dp, degree of polymerization
(i.e. number of monosaccharides); GlcA,
-D-glucuronate; IdoA,
-L-iduronate; HexA,
unspecified hexuronate;
HexA,
4,5-unsaturated
hexuronate; IdoA(2-OSO3),
-L-iduronate
2-sulfate; GalNAc,
-D-N-acetylgalactosamine;
GalNAc(4-OSO3),
-D-N-acetylgalactosamine 4-sulfate;
GalNAc(6-OSO3),
-D-N-acetylgalactosamine 6-sulfate; GalNAc(4,6-OSO3),
-D-N-acetylgalactosamine 4,6-disulfate; MDCK, Madin-Darby canine kidney.
2 H. Rahmoune, P. S. Rudland, J. T. Gallagher, and D. G. Fernig, submitted for publication.
3 Rahmoune, H., Chen, H.-L., Gallagher, J. T., Rudland, P. S., and Fernig, D. G. (1998) J. Biol. Chem., in press.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|